ArticlePharmacogenetics and genomics2013
Polygenic heritability estimates in pharmacogenetics: focus on asthma and related phenotypes.
Article in Pharmacogenetics and genomics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- A Pharmacogenetic Prediction Model of Progression-Free Survival in Breast Cancer using Genome-Wide Genotyping Data from CALGB 40502 (Alliance).Clinical pharmacology and therapeutics · 2019Trial
- Chronic Inflammation in Asthma: Looking Beyond the Th2 Cell.Immunological reviews · 2025Review
- Pharmacogenetic Information on Drug Labels of the Italian Agency of Medicines (AIFA): Actionability and Comparison Across Other Regulatory Agencies.Clinical and translational science · 2025Article
- Pharmacogenetics of childhood uncontrolled asthma.Expert review of clinical immunology · 2025Review
- Circulating microRNAs associated with bronchodilator response in childhood asthma.BMC pulmonary medicine · 2024Article
- Review
- Pharmacogenomic and Statistical Analysis.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Immunogenetics and pharmacogenetics of allergic asthma in Africa.Frontiers in allergy · 2023Review
- A genome-wide association study of bronchodilator response in participants of European and African ancestry from six independent cohorts.ERJ open research · 2022Article
- Pharmacogenetics of Bronchodilator Response: Future Directions.Current allergy and asthma reports · 2021Review
- A polygenic risk score for asthma in a large racially diverse population.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2021Article
- Genome-Wide Approach to Measure Variant-Based Heritability of Drug Outcome Phenotypes.Clinical pharmacology and therapeutics · 2021Article
- Age by Single Nucleotide Polymorphism Interactions on Bronchodilator Response in Asthmatics.Journal of personalized medicine · 2021Article
- Role of Epigenetics in the Pathogenesis, Treatment, Prediction, and Cellular Transformation of Asthma.Mediators of inflammation · 2021Review
- Native American Ancestry and Air Pollution Interact to Impact Bronchodilator Response in Puerto Rican Children with Asthma.Ethnicity & disease · 2021Article
- Article
- Methods and implementation of a pediatric asthma pharmacogenomic study in the emergency department setting.Pharmacogenetics and genomics · 2020Article
- Early origins of allergy and asthma (ARIES): study protocol for a prospective prenatal birth cohort in Chile.BMC pediatrics · 2020Article
- An epistatic interaction between pre-natal smoke exposure and socioeconomic status has a significant impact on bronchodilator drug response in African American youth with asthma.BioData mining · 2020Article
- The nasal methylome as a biomarker of asthma and airway inflammation in children.Nature communications · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Although accurate measures of heritability are required to understand the pharmacogenetic basis of drug treatment response, these are generally not available, as it is unfeasible to give medications to individuals for which treatment is not indicated. Using a polygenic linear mixed modeling approach, we estimated lower bounds on the heritability of asthma and the heritability of two related drug-response phenotypes, bronchodilator response and airway hyperreactivity, using genome-wide single nucleotide polymorphism (SNP) data from existing asthma cohorts. Our estimate of the heritability for bronchodilator response is 28.5% (SE 16%, P=0.043) and airway hyperresponsiveness is 51.1% (SE 34%, P=0.064), whereas we estimate asthma genetic liability at 61.5% (SE 16%, P<0.001). Our results agree with the previously published estimates of the heritability of these traits, suggesting that the linear mixed modeling method is useful for computing the heritability of other pharmacogenetic traits. Furthermore, our results indicate that multiple SNP main effects, including SNPs as yet unidentified by genome-wide association study methods, together explain a sizable portion of the heritability of these traits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.